Peapack-Gladstone Financial Corp’s ANI Pharmaceuticals ANIP Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$829K	Buy	10,011 +11	+0.1%	+$882	0.01%	432
2026 Q1	$769K	Hold	10,000	–	–	0.01%	426
2025 Q4	$789K	Hold	10,000	–	–	0.01%	422
2025 Q3	$916K	Hold	10,000	–	–	0.01%	418
2025 Q2	$653K	Hold	10,000	–	–	0.01%	446
2025 Q1	$670K	Hold	10,000	–	–	0.01%	436
2024 Q4	$553K	Hold	10,000	–	–	0.01%	464
2024 Q3	$597K	Hold	10,000	–	–	0.01%	457
2024 Q2	$637K	Hold	10,000	–	–	0.01%	443
2024 Q1	$691K	Hold	10,000	–	–	0.01%	438
2023 Q4	$551K	Hold	10,000	–	–	0.01%	468
2023 Q3	$581K	Hold	10,000	–	–	0.01%	449
2023 Q2	$538K	Hold	10,000	–	–	0.01%	469
2023 Q1	$397K	Hold	10,000	–	–	0.01%	515
2022 Q4	$402K	Hold	10,000	–	–	0.01%	497
2022 Q3	$321K	Hold	10,000	–	–	0.01%	533
2022 Q2	$297K	Hold	10,000	–	–	0.01%	517
2022 Q1	$281K	Buy	+10,000	New	+$373K	0.01%	569

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Peapack-Gladstone Financial Corp's ANIP Position: Q2 2026 in Review

Peapack-Gladstone Financial Corp increased its ANI Pharmaceuticals (ANIP) stake by 0.11% in Q2 2026, buying an estimated $882 and bringing the position to 10,011 shares worth $829K. The position accounts for 0.01% of the portfolio, ranked #432.

Peapack-Gladstone Financial Corp first reported a position in ANIP in Q1 2022 and has held it in 18 quarters since. The position peaked at $916K in Q3 2025. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Peapack-Gladstone Financial Corp held 10,011 shares of ANI Pharmaceuticals worth $829K as of Q2 2026.
Peapack-Gladstone Financial Corp bought 11 ANI Pharmaceuticals shares in Q2 2026, an estimated $882.
ANI Pharmaceuticals made up 0.01% of Peapack-Gladstone Financial Corp's portfolio in Q2 2026, its #432 holding.
Peapack-Gladstone Financial Corp first reported a position in ANI Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
Peapack-Gladstone Financial Corp's ANI Pharmaceuticals position peaked at $916K in Q3 2025.
308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q2 2026, filed 14 Aug 2026.